Get the Stockscreener App
161.99
6.33%
9.64
Guardant Health Inc stock is traded at $161.99, with a volume of 4.56M.
It is up +6.33% in the last 24 hours and up +7.97% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$152.35
Open:
$162.5
24h Volume:
4.56M
Relative Volume:
1.79
Market Cap:
$21.48B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-47.64
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
+9.95%
1M Performance:
+7.97%
6M Performance:
+42.05%
1Y Performance:
+295.29%
1-Day Range:
$160.01
$176.58
1-Week Range:
$140.86
$176.58
52-Week Range:
$40.35
$176.58
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
161.99 | 19.29B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
574.38 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
195.02 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.07 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
235.07 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
138.37 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Patrick Dempsey Urges Screening With Guardant's Shield Blood Test - Stock Titan
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer - New Castle News
Freenome secures FDA nod for blood-based colorectal cancer test - MedTech Dive
FDA approves Freenome’s blood test for colorectal cancer screening - WTVB
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Orbimed Advisors LLC Buys Shares of 435,200 Guardant Health, Inc. $GH - MarketBeat
Styrax Capital LP Purchases 18,411 Shares of Guardant Health, Inc. $GH - MarketBeat
First Light Asset Management LLC Sells 14,452 Shares of Guardant Health, Inc. $GH - MarketBeat
Caxton Associates LLP Invests $831,000 in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) stock price, news, quote and history - Yahoo Finance UK
Guardant Health, Inc. $GH Shares Sold by Aristotle Atlantic Partners LLC - MarketBeat
Guardant Health Inc (GH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guardant Health, Inc. (GH) Stock Forecasts - Yahoo Finance
Guardant Health: An Expensive Price For A Great Company - Seeking Alpha
Guardant Health, Inc. $GH Shares Sold by Atika Capital Management LLC - MarketBeat
Guardant Health Inc (GH) Institutional Confidence - TradingKey
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Hsbc Holdings PLC Has $9.13 Million Stake in Guardant Health, Inc. $GH - MarketBeat
Principal Financial Group Inc. Has $17.07 Million Stock Position in Guardant Health, Inc. $GH - MarketBeat
GH|Guardant Health Inc|Price:147.330|Chg%:-2.870 - TradingKey
Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Form 4 Guardant Health Inc For: 22 July By Investing.com - Investing.com South Africa
Temasek Holdings Private Ltd Sells 58,526 Shares of Guardant Health, Inc. $GH - MarketBeat
Jennison Associates LLC Sells 966,559 Shares of Guardant Health, Inc. $GH - MarketBeat
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Biomarker Collaboration and Licensing Deals Report 2016-2026Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More - Yahoo Finance
Strong Results Boosted Guardant Health (GH) in Q2 - Yahoo Finance
Guardant Health, Inc. $GH Stock Position Raised by WCM Investment Management LLC - MarketBeat
Amova Asset Management Americas Inc. Sells 156,738 Shares of Guardant Health, Inc. $GH - MarketBeat
EBITDA per share of Guardant Health, Inc. – LSX:A2N5RY - TradingView
Guardant Health Surges 53% on UnitedHealth Coverage Deal — "Single-Drop Blood Test for Cancer" Becomes Reality - finance.biggo.com
Guardant Health Falls as Recent Rally Appears to Cool - Quiver Quantitative
Lobbying Update: $180,000 of GUARDANT HEALTH lobbying was just disclosed - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: Unpacking a 48% Revenue Growth in the Diagnostics Sector - DirectorsTalk Interviews
Guardant Health, Inc. $GH Stock Position Raised by D.A. Davidson & CO. - MarketBeat
Allspring Global Investments Holdings LLC Lowers Position in Guardant Health, Inc. $GH - MarketBeat
Responsive Playbooks and the GH Inflection - Stock Traders Daily
Future Fund LLC Increases Position in Guardant Health, Inc. $GH - MarketBeat
Fifth Third Bancorp Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Form 144 Guardant Health For: 16 July By Investing.com - Investing.com Nigeria
Guardant Health director Tariq Musa sells $18,941 in stock By Investing.com - Investing.com Nigeria
Form 4 Guardant Health Inc For: 16 July By Investing.com - Investing.com Nigeria
GH Maintains Rating by Guggenheim -- Price Target Raised to $190 - GuruFocus
Guardant Health director Tariq Musa sells $18,941 in stock - Investing.com
Musa Tariq plans sale of Guardant Health (NASDAQ: GH) common stock - Stock Titan
Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN) - Benzinga
Guggenheim raises Guardant Health stock price target on Shield data - Investing.com
Guggenheim raises Guardant Health stock price target on Shield data By Investing.com - Investing.com Canada
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hidalgo Medina Manuel | Director |
Jul 17 '26 |
Option Exercise |
0.00 |
232 |
0 |
5,306 |
| Tariq Musa | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
250 |
0 |
11,298 |
| Tariq Musa | Director |
Jul 16 '26 |
Sale |
163.29 |
116 |
18,942 |
11,182 |
0.55%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):